RxTrials Institute Drug Pipeline Alert

Peripheral arterial disease is the narrowing or blockage of arteries that results in poor blood flow to the arms and legs.

The randomized, double-blind, placebo-controlled, single-center, single-ascending dose study will evaluate the safety and pharmacokinetic profile of the drug. A total of 74 healthy adult male subjects will be enrolled in eight dose groups, receiving intravenous doses of the drug ranging from 3 mcg to 360 mcg, Sucampo said.